4
Changes in Ownership
Keros Therapeutics, Inc. Filed Acc 0001209191-24-001155
Chief Financial Officer sold 40,000 shares at $45.29 ($1,811,600)
- Chief Financial Officer acquired 40,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Regnante Keith Chief Financial Officer | 2023-11-04 | Option exercise | +40,000 | $16.00 | $640,000 | 40,000 | D |
| Regnante Keith Chief Financial Officer | 2023-11-04 | Sale | −40,000 | $45.29 | $1,811,600 | 0 | D |
| Derivatives | |||||||
| Regnante Keith Chief Financial Officer | 2024-01-04 | Option exercise · Employee Stock Option (right to buy) | −40,000 | 53,622 | D | ||
| Open-market sales · 40,000 sh · avg $45.29 · $1,811,600 | |||||||
Loading xslF345X05/doc4.xml…